vs
Side-by-side financial comparison of EyePoint, Inc. (EYPT) and Marygold Companies, Inc. (MGLD). Click either name above to swap in a different company.
Marygold Companies, Inc. is the larger business by last-quarter revenue ($7.6M vs $5.3M, roughly 1.4× EyePoint, Inc.). Marygold Companies, Inc. runs the higher net margin — -7.5% vs -1114.3%, a 1106.8% gap on every dollar of revenue. On growth, Marygold Companies, Inc. posted the faster year-over-year revenue change (-4.5% vs -43.7%). Over the past eight quarters, Marygold Companies, Inc.'s revenue compounded faster (-1.5% CAGR vs -40.8%).
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
EYPT vs MGLD — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.3M | $7.6M |
| Net Profit | $-59.4M | $-576.0K |
| Gross Margin | — | 74.0% |
| Operating Margin | -1166.8% | -8.3% |
| Net Margin | -1114.3% | -7.5% |
| Revenue YoY | -43.7% | -4.5% |
| Net Profit YoY | -92.8% | 67.0% |
| EPS (diluted) | $-0.85 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | $5.3M | $7.2M | ||
| Q1 25 | $24.5M | $7.0M | ||
| Q4 24 | $11.6M | $8.0M | ||
| Q3 24 | $10.5M | $7.9M | ||
| Q2 24 | $9.5M | $8.3M | ||
| Q1 24 | $11.7M | $7.9M |
| Q4 25 | — | $-576.0K | ||
| Q3 25 | — | $-356.0K | ||
| Q2 25 | $-59.4M | $-1.5M | ||
| Q1 25 | $-45.2M | $-1.0M | ||
| Q4 24 | $-41.4M | $-1.7M | ||
| Q3 24 | $-29.4M | $-1.6M | ||
| Q2 24 | $-30.8M | $-1.9M | ||
| Q1 24 | $-29.3M | $-529.0K |
| Q4 25 | — | 74.0% | ||
| Q3 25 | — | 77.0% | ||
| Q2 25 | — | 67.8% | ||
| Q1 25 | — | 75.0% | ||
| Q4 24 | — | 74.1% | ||
| Q3 24 | 93.0% | 73.1% | ||
| Q2 24 | 85.2% | 72.5% | ||
| Q1 24 | 93.5% | 70.5% |
| Q4 25 | — | -8.3% | ||
| Q3 25 | — | -18.2% | ||
| Q2 25 | -1166.8% | -16.5% | ||
| Q1 25 | -199.7% | -21.4% | ||
| Q4 24 | -390.4% | -22.8% | ||
| Q3 24 | -311.2% | -27.4% | ||
| Q2 24 | -364.5% | -33.3% | ||
| Q1 24 | -285.2% | -18.7% |
| Q4 25 | — | -7.5% | ||
| Q3 25 | — | -5.1% | ||
| Q2 25 | -1114.3% | -20.4% | ||
| Q1 25 | -184.8% | -14.4% | ||
| Q4 24 | -357.3% | -21.8% | ||
| Q3 24 | -279.0% | -20.1% | ||
| Q2 24 | -325.3% | -22.5% | ||
| Q1 24 | -250.6% | -6.7% |
| Q4 25 | — | $-0.01 | ||
| Q3 25 | — | $-0.01 | ||
| Q2 25 | $-0.85 | $-0.04 | ||
| Q1 25 | $-0.65 | $-0.02 | ||
| Q4 24 | $-0.65 | $-0.04 | ||
| Q3 24 | $-0.54 | $-0.04 | ||
| Q2 24 | $-0.58 | $-0.05 | ||
| Q1 24 | $-0.55 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $255.7M | $11.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.0M | $22.7M |
| Total Assets | $301.1M | $27.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $11.6M | ||
| Q3 25 | — | $12.5M | ||
| Q2 25 | $255.7M | $12.8M | ||
| Q1 25 | $318.2M | $15.6M | ||
| Q4 24 | $370.9M | $14.9M | ||
| Q3 24 | $253.8M | $17.5M | ||
| Q2 24 | $280.2M | $15.0M | ||
| Q1 24 | $299.3M | $16.1M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $22.9M | ||
| Q2 25 | $246.0M | $23.0M | ||
| Q1 25 | $298.4M | $24.3M | ||
| Q4 24 | $336.5M | $23.4M | ||
| Q3 24 | $218.7M | $25.5M | ||
| Q2 24 | $228.3M | $26.6M | ||
| Q1 24 | $249.9M | $28.4M |
| Q4 25 | — | $27.8M | ||
| Q3 25 | — | $28.4M | ||
| Q2 25 | $301.1M | $30.4M | ||
| Q1 25 | $362.6M | $33.5M | ||
| Q4 24 | $418.5M | $33.0M | ||
| Q3 24 | $300.9M | $35.9M | ||
| Q2 24 | $324.2M | $32.9M | ||
| Q1 24 | $329.2M | $33.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-62.6M | $-908.0K |
| Free Cash FlowOCF − Capex | $-63.8M | — |
| FCF MarginFCF / Revenue | -1196.5% | — |
| Capex IntensityCapex / Revenue | 22.9% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-194.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-908.0K | ||
| Q3 25 | — | $-533.0K | ||
| Q2 25 | $-62.6M | $-3.3M | ||
| Q1 25 | $-53.1M | $-1.2M | ||
| Q4 24 | $-35.8M | $-770.0K | ||
| Q3 24 | $-39.0M | $-893.0K | ||
| Q2 24 | $-20.2M | $-1.9M | ||
| Q1 24 | $-31.2M | $-658.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-562.0K | ||
| Q2 25 | $-63.8M | $-3.4M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $-36.2M | $-776.0K | ||
| Q3 24 | $-40.6M | $-940.0K | ||
| Q2 24 | $-21.1M | $-2.0M | ||
| Q1 24 | $-32.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -8.1% | ||
| Q2 25 | -1196.5% | -46.8% | ||
| Q1 25 | -218.4% | — | ||
| Q4 24 | -312.7% | -9.7% | ||
| Q3 24 | -385.8% | -11.9% | ||
| Q2 24 | -222.4% | -23.8% | ||
| Q1 24 | -277.0% | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | 22.9% | 0.7% | ||
| Q1 25 | 1.1% | 0.0% | ||
| Q4 24 | 3.3% | 0.1% | ||
| Q3 24 | 15.0% | 0.6% | ||
| Q2 24 | 9.5% | 0.7% | ||
| Q1 24 | 10.2% | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EYPT
Segment breakdown not available.
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
